News

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...
Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.
GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...
British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that ...
British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...
GSK is taking to the airwaves to talk RSV, presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games.
GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that offered some respite after recent setbacks.
Drugmaker GSK said on Wednesday that Q2 revenues had grown as a strong specialty medicines performance drove sales and core operating profit growth.
GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...
Investing.com -- GSK (LON: GSK) on Wednesday raised its full-year earnings guidance after posting a 35% rise in second-quarter profit, supported by continued strength in its HIV and oncology ...